In our study, we applied baseline RBC balanced immuno-inflammatory parameters, along with the well-studied markers such as NLR, LMR, and PLR, for the prediction of PFS and OS in hormone receptor-positive, HER2-negative ABC patients treated with CDKI. The gene discussed is ERBB2; the disease is aneurysmal bone cyst.